Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Unveiling the Potential of Serum MiR-483-5p: A Promising Diagnostic and Prognostic Biomarker in OLP and OSCC Patients by In silico Analysis of Differential Gene Expression

Author(s): Pouria Soltaninezhad, Fatemeh Arab, Nooshin Mohtasham, Mohammadhossein FakherBaheri, Nima Nikbin Kavishahi, Seyed Hamid Aghaee-Bakhtiari, Reza Zare-Mahmoodabadi, Atessa Pakfetrat, Kiarash Izadi Taban and Farnaz Mohajertehran*

Volume 30, Issue 4, 2024

Published on: 17 January, 2024

Page: [310 - 322] Pages: 13

DOI: 10.2174/0113816128276149240108163407

Price: $65

Abstract

Abstract: Background: Oral squamous cell carcinoma (OSCC) and oral lichen planus (OLP) are two separate conditions affecting the mouth and result in varying clinical outcomes and levels of malignancy. Achieving early diagnosis and effective therapy planning requires the identification of reliable diagnostic biomarkers for these disorders. MicroRNAs (miRNAs) have recently received attention as powerful biomarkers for various illnesses, including cancer. In particular, miR-483-5p is a promising diagnostic and prognostic biomarker in various cancers. Therefore, this study aimed to investigate the role of serum miR-483-5p in the diagnosis and prognosis of OLP and OSCC patients by in silico analysis of differential gene expression.

Methods: GSE23558 and GSE52130 data sets were selected, and differential gene expression analysis was performed using microarray data from GSE52130 and GSE23558. The analysis focused on comparing OLP and OSCC samples with normal samples. The genes intersected through the differential gene expression analysis were then extracted to determine the overlapping genes among the upregulated or downregulated DEGs. The downregulated genes among the DEGs were subsequently imported into the miRWalk database to search for potential target genes of miRNA 483-5p that lacked validation. To gain insight into the biological pathways associated with the DEGs, we conducted pathway analysis utilizing tools, such as Enrichr. Additionally, the cellular components associated with these DEGs were investigated by analyzing the String database. On the other hand, blood serum samples were collected from 35 OSCC patients, 34 OLP patients, and 34 healthy volunteers. The expression level of miR-483-5p was determined using quantitative reverse transcription polymerase chain reaction (RT-qPCR). The Kruskal-Wallis test was utilized to investigate the considerable correlation. Moreover, this study explored the prognostic value of miR-483-5p through its association with clinicopathological parameters in OSCC patients.

Results: The results showed that serum expression of miR-483-5p was considerably higher in OSCC patients compared to OLP patients and healthy controls (p 0.0001) and that this difference was statistically significant. Furthermore, elevated miR-483-5p expression was associated with tumor size, lymph node metastasis, and stage of tumor nodal metastasis in OSCC patients (p 0.001, p 0.038, and p 0.0001, respectively). In silico analysis found 71 upregulated genes at the intersection of upregulated DEGs and 44 downregulated genes at the intersection of downregulated DEGs, offering insight into the potential underlying mechanisms of miR-483-5p’s engagement in OSCC and OLP. The majority of these DEGs were found to be involved in autophagy pathways, but DEGs involved in the histidine metabolism pathway showed significant results. Most of these DEGs were located in the extracellular region. After screening for downregulated genes that were invalidated, miRNA 483-5p had 7 target genes.

Conclusion: This study demonstrates the potential of serum miR-483-5p as a promising diagnostic and prognostic biomarker in OSCC and OLP patients. Its upregulation in OSCC patients and its association with advanced tumor stage and potential metastasis suggest the involvement of miR-483-5p in critical signaling pathways involved in cell proliferation, apoptosis, and cell cycle regulation, making it a reliable indicator of disease progression. Nevertheless, additional experimental studies are essential to validate these findings and establish a foundation for the advancement of targeted therapies and personalized treatment approaches.

« Previous
[1]
Zhou Y, Hong L. Prediction value of miR-483 and miR-214 in prognosis and multidrug resistance of esophageal squamous cell carcinoma. Genet Test Mol Biomarkers 2013; 17(6): 470-4.
[http://dx.doi.org/10.1089/gtmb.2012.0518] [PMID: 23721345]
[2]
Yong FL, Law CW, Wang CW. Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer. BMC Cancer 2013; 13(1): 280.
[http://dx.doi.org/10.1186/1471-2407-13-280] [PMID: 23758639]
[3]
Rachagani S, Macha MA, Menning MS, et al. Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model. Oncotarget 2015; 6(37): 40295-309.
[http://dx.doi.org/10.18632/oncotarget.5641] [PMID: 26516699]
[4]
Amirkhah R, Schmitz U, Linnebacher M, Wolkenhauer O, Farazmand A. MicroRNA-mRNA interactions in colorectal cancer and their role in tumor progression. Genes Chromoso Cancer 2015; 54(3): 129-41.
[http://dx.doi.org/10.1002/gcc.22231] [PMID: 25620079]
[5]
Farshbaf A, Zare R, Mohajertehran F, Mohtasham N. New diagnostic molecular markers and biomarkers in odontogenic tumors. Mol Biol Rep 2021; 48(4): 3617-28.
[http://dx.doi.org/10.1007/s11033-021-06286-0] [PMID: 33822294]
[6]
Hong L, Han Y, Li S, et al. The malignant phenotype-associated microRNA in gastroenteric, hepatobiliary and pancreatic carcinomas. Expert Opin Biol Ther 2010; 10(12): 1693-701.
[http://dx.doi.org/10.1517/14712598.2010.532482] [PMID: 20977295]
[7]
Liu M, Roth A, Yu M, et al. The IGF2 intronic miR-483 selectively enhances transcription from IGF2 fetal promoters and enhances tumorigenesis. Genes Dev 2013; 27(23): 2543-8.
[http://dx.doi.org/10.1101/gad.224170.113] [PMID: 24298054]
[8]
Watson JA, Bryan K, Williams R, et al. miRNA profiles as a predictor of chemoresponsiveness in Wilms’ tumor blastema. PLoS One 2013; 8(1): e53417.
[http://dx.doi.org/10.1371/journal.pone.0053417] [PMID: 23308219]
[9]
Yu X, Li Z, Chan MTV, Wu WKK. The roles of microRNAs in Wilms’ tumors. Tumour Biol 2016; 37(2): 1445-50.
[http://dx.doi.org/10.1007/s13277-015-4514-8] [PMID: 26634744]
[10]
Wang L, Shi M, Hou S, et al. MiR-483-5p suppresses the proliferation of glioma cells via directly targeting ERK1. FEBS Lett 2012; 586(9): 1312-7.
[http://dx.doi.org/10.1016/j.febslet.2012.03.035] [PMID: 22465663]
[11]
chen Y, Wang H, Zhu S, Lan X. miR-483-5p promotes esophageal cancer progression by targeting KCNQ1. Biochem Biophys Res Commun 2020; 531(4): 615-21.
[http://dx.doi.org/10.1016/j.bbrc.2020.07.037] [PMID: 32819715]
[12]
Zhou W, Yang W, Ma J, et al. Role of miR-483 in digestive tract cancers: from basic research to clinical value. J Cancer 2018; 9(2): 407-14.
[http://dx.doi.org/10.7150/jca.21394] [PMID: 29344287]
[13]
Che G, Gao H, Tian J, Hu Q, Xie H, Zhang Y. MicroRNA-483-3p promotes proliferation, migration, and invasion and induces chemoresistance of wilms’ tumor cells. Pediatr Dev Pathol 2020; 23(2): 144-51.
[http://dx.doi.org/10.1177/1093526619873491] [PMID: 31498707]
[14]
Zhou W, Yang W, Yang J, et al. miR-483 promotes the development of colorectal cancer by inhibiting the expression level of EI24. Mol Med Rep 2021; 24(2): 567.
[http://dx.doi.org/10.3892/mmr.2021.12206] [PMID: 34109432]
[15]
Ghazi N, Aali N, Shahrokhi VR, Mohajertehran F, Saghravanian N. Relative expression of SOX2 and OCT4 in oral squamous cell carcinoma and oral epithelial dysplasia. Rep Biochem Mol Biol 2020; 9(2): 171-9.
[http://dx.doi.org/10.29252/rbmb.9.2.171] [PMID: 33178866]
[16]
Al Rawi N, Elmabrouk N, Abu Kou R, Mkadmi S, Rizvi Z, Hamdoon Z. The role of differentially expressed salivary microRNA in oral squamous cell carcinoma. A systematic review. Arch Oral Biol 2021; 125: 105108.
[http://dx.doi.org/10.1016/j.archoralbio.2021.105108] [PMID: 33756383]
[17]
Ghosh P, Jana A, Thomas J. Erosive oral lichen planus inflicts higher cellular stress than reticular type. J Oral Maxillofac Pathol 2021; 25(2): 279-85.
[http://dx.doi.org/10.4103/0973-029X.325127] [PMID: 34703122]
[18]
Mohtasham N, Ayatollahi H, Saghravanian N, et al. Evaluation of tissue and serum expression levels of lactate dehydrogenase isoenzymes in patients with head and neck squamous cell carcinoma. Anticancer Agents Med Chem 2020; 19(17): 2072-8.
[http://dx.doi.org/10.2174/1871520619666191014160818] [PMID: 31660843]
[19]
Inchanalkar M, Srivatsa S, Ambatipudi S, et al. Genome-wide DNA methylation profiling of HPV-negative leukoplakia and gingivobuccal complex cancers. Clin Epigenetics 2023; 15(1): 93.
[http://dx.doi.org/10.1186/s13148-023-01510-z] [PMID: 37245006]
[20]
Danielsson K, Coates P, Ebrahimi M, Nylander E, Wahlin Y, Nylander K. Genes involved in epithelial differentiation and development are differentially expressed in oral and genital lichen planus epithelium compared to normal epithelium. Acta Derm Venereol 2014; 94(5): 526-30.
[http://dx.doi.org/10.2340/00015555-1803] [PMID: 24626344]
[21]
Szklarczyk D, Kirsch R, Koutrouli M, et al. The STRING database in 2023: Protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res 2023; 51(D1): D638-46.
[http://dx.doi.org/10.1093/nar/gkac1000] [PMID: 36370105]
[22]
Shannon P, Markiel A, Ozier O, et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13(11): 2498-504.
[http://dx.doi.org/10.1101/gr.1239303] [PMID: 14597658]
[23]
Murugan AK, Munirajan AK, Tsuchida N. Ras oncogenes in oral cancer: The past 20 years. Oral Oncol 2012; 48(5): 383-92.
[http://dx.doi.org/10.1016/j.oraloncology.2011.12.006] [PMID: 22240207]
[24]
Mohtasham N, Anvari K, Memar B, et al. Expression of E-cadherin and matrix metalloproteinase-9 in oral squamous cell carcinoma and histologically negative surgical margins and association with clinicopathological parameters. Rom J Morphol Embryol 2014; 55(1): 117-21.
[PMID: 24715175]
[25]
Ries J, Vairaktaris E, Kintopp R, Baran C, Neukam FW, Nkenke E. Alterations in miRNA expression patterns in whole blood of OSCC patients. In Vivo 2014; 28(5): 851-61.
[PMID: 25189899]
[26]
Wang W, Wang M, Ahmed MMS, et al. FAM3B serves as a biomarker for the development and malignancy of oral lichen planus. Int J Gen Med 2022; 15: 763-76.
[http://dx.doi.org/10.2147/IJGM.S346617] [PMID: 35082524]
[27]
Li QL, Mao J, Meng XY. Comprehensive characterization of immune landscape based on tumor microenvironment for oral squamous cell carcinoma prognosis. Vaccines 2022; 10(9): 1521.
[http://dx.doi.org/10.3390/vaccines10091521] [PMID: 36146599]
[28]
Wang L, Wu W, Chen J, Li Y, Xu M, Cai Y. miR-122 and miR-199 synergistically promote autophagy in oral lichen planus by targeting the Akt/mTOR pathway. Int J Mol Med 2019; 43(3): 1373-81.
[http://dx.doi.org/10.3892/ijmm.2019.4068] [PMID: 30664152]
[29]
Tan Y-Q, Zhang J, Du G-F, Lu R, Chen G-Y, Zhou G. Altered autophagy-associated genes expression in T cells of oral lichen planus correlated with clinical features. Mediat Inflamm 2016; 2016: 4867368.
[http://dx.doi.org/10.1155/2016/4867368]
[30]
Dong W, Chen Y, Qian N, et al. SATB2 knockdown decreases hypoxia-induced autophagy and stemness in oral squamous cell carcinoma. Oncol Lett 2020; 20(1): 794-802.
[http://dx.doi.org/10.3892/ol.2020.11589] [PMID: 32566006]
[31]
Chen G, Liu H, Zhang Y, et al. Silencing PFKP inhibits starvation-induced autophagy, glycolysis, and epithelial mesenchymal transition in oral squamous cell carcinoma. Exp Cell Res 2018; 370(1): 46-57.
[http://dx.doi.org/10.1016/j.yexcr.2018.06.007] [PMID: 29894707]
[32]
Song Q, Xu Y, Yang C, et al. miR-483-5p promotes invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1 and ALCAM. Cancer Res 2014; 74(11): 3031-42.
[http://dx.doi.org/10.1158/0008-5472.CAN-13-2193] [PMID: 24710410]
[33]
Huang G, Zhang J, Qing G, et al. Downregulation of miR-483-5p inhibits TGF-β1-induced EMT by targeting RhoGDI1 in pulmonary fibrosis. Mol Med Rep 2021; 24(1): 538.
[http://dx.doi.org/10.3892/mmr.2021.12177]
[34]
Li XZ, Tu YJ, Zhou T, et al. MicroRNA-483-5p predicts poor prognosis and promotes cancer metastasis by targeting EGR3 in nasopharyngeal carcinoma. Front Oncol 2021; 11: 720835.
[http://dx.doi.org/10.3389/fonc.2021.720835] [PMID: 34722264]
[35]
Abdelaleem OO, Fouad NA, Shaker OG, et al. Serum miR-224, miR-760, miR-483-5p, miR-378 and miR-375 as potential novel biomarkers in rheumatoid arthritis. Int J Clin Pract 2021; 75(11): e14651.
[http://dx.doi.org/10.1111/ijcp.14651] [PMID: 34310809]
[36]
Shao H, Zhang Y, Yan J, et al. Upregulated microRNA-483-3p is an early event in Pancreatic Ductal Adenocarcinoma (PDAC) and as a powerful liquid biopsy biomarker in PDAC. OncoTargets Ther 2021; 14: 2163-75.
[http://dx.doi.org/10.2147/OTT.S288936] [PMID: 33790579]
[37]
Giuliani A, Matacchione G, Ramini D, et al. Circulating miR-320b and miR-483-5p levels are associated with COVID-19 in-hospital mortality. Mech Ageing Dev 2022; 202: 111636.
[http://dx.doi.org/10.1016/j.mad.2022.111636] [PMID: 35122770]
[38]
Yang ZG, Ma XD, He ZH, Guo Y. miR-483-5p promotes prostate cancer cell proliferation and invasion by targeting RBM5. Int Braz J Urol 2017; 43(6): 1060-7.
[http://dx.doi.org/10.1590/s1677-5538.ibju.2016.0595] [PMID: 28727371]
[39]
Xu H, Yang Y, Zhao H, et al. Serum miR-483-5p: A novel diagnostic and prognostic biomarker for patients with oral squamous cell carcinoma. Tumour Biol 2016; 37(1): 447-53.
[http://dx.doi.org/10.1007/s13277-015-3514-z] [PMID: 26224475]
[40]
Bertero T, Bourget-Ponzio I, Puissant A, et al. Tumor suppressor function of miR-483-3p on squamous cell carcinomas due to its pro-apoptotic properties. Cell Cycle 2013; 12(14): 2183-93.
[http://dx.doi.org/10.4161/cc.25330] [PMID: 24067364]
[41]
Ghantous Y, Schussel JL, Brait M. Tobacco and alcohol-induced epigenetic changes in oral carcinoma. Curr Opin Oncol 2018; 30(3): 152-8.
[http://dx.doi.org/10.1097/CCO.0000000000000444] [PMID: 29538041]
[42]
Rumgay H, Murphy N, Ferrari P, Soerjomataram I. Alcohol and cancer: Epidemiology and biological mechanisms. Nutrients 2021; 13(9): 3173.
[http://dx.doi.org/10.3390/nu13093173] [PMID: 34579050]
[43]
Yete S, D’Souza W, Saranath D. High-risk human papillomavirus in oral cancer: Clinical implications. Oncology 2018; 94(3): 133-41.
[http://dx.doi.org/10.1159/000485322] [PMID: 29241220]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy